KR20220042200A - 상처 치유 촉진용 조성물 및 방법 - Google Patents

상처 치유 촉진용 조성물 및 방법 Download PDF

Info

Publication number
KR20220042200A
KR20220042200A KR1020227006955A KR20227006955A KR20220042200A KR 20220042200 A KR20220042200 A KR 20220042200A KR 1020227006955 A KR1020227006955 A KR 1020227006955A KR 20227006955 A KR20227006955 A KR 20227006955A KR 20220042200 A KR20220042200 A KR 20220042200A
Authority
KR
South Korea
Prior art keywords
peptide
enos
arg
lys
ccr10
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227006955A
Other languages
English (en)
Korean (ko)
Inventor
리차드 디. 민샬
젠룽 첸
Original Assignee
더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 filed Critical 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이
Publication of KR20220042200A publication Critical patent/KR20220042200A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020227006955A 2019-07-29 2020-07-28 상처 치유 촉진용 조성물 및 방법 Pending KR20220042200A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962879717P 2019-07-29 2019-07-29
US62/879,717 2019-07-29
PCT/US2020/043813 WO2021021774A1 (en) 2019-07-29 2020-07-28 Composition and method for promoting wound healing

Publications (1)

Publication Number Publication Date
KR20220042200A true KR20220042200A (ko) 2022-04-04

Family

ID=72047146

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227006955A Pending KR20220042200A (ko) 2019-07-29 2020-07-28 상처 치유 촉진용 조성물 및 방법

Country Status (7)

Country Link
US (1) US20220265759A1 (enExample)
EP (1) EP4003393A1 (enExample)
JP (1) JP7636812B2 (enExample)
KR (1) KR20220042200A (enExample)
CA (1) CA3148980A1 (enExample)
MX (1) MX2022001020A (enExample)
WO (1) WO2021021774A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116121305B (zh) * 2023-01-03 2024-11-22 广州医科大学附属第五医院 间充质干细胞在糖尿病相关疾病中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4708934A (en) 1984-09-27 1987-11-24 Unigene Laboratories, Inc. α-amidation enzyme
JPS6229997A (ja) 1985-04-08 1987-02-07 Sankyo Co Ltd Ｃ末端にプロリンアミドを有するペプチドの製法
US4978532A (en) 1989-08-11 1990-12-18 Pharmedic Co. Dosage form for administration of dehydroepiandrosterone
US5580751A (en) 1990-09-14 1996-12-03 Carlsberg A/S Process for the preparation of C-terminally amidated peptides
WO1993002697A1 (en) 1991-08-08 1993-02-18 Amylin Pharmaceuticals, Inc. Production of peptide amides
DE69332197T2 (de) 1992-03-13 2003-04-17 Organon Teknika B.V., Boxtel Epstein-Barr-Virus verwandte Peptide und Nukleinsäuresegmenten
US5709878A (en) 1996-08-02 1998-01-20 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
GB9708918D0 (en) 1997-05-01 1997-06-25 Ppl Therapeutics Scotland Ltd Methods
AUPP697698A0 (en) * 1998-11-06 1998-12-03 St. Vincent's Institute Of Medical Research Regulation of enzyme activity
EP1553973A4 (en) * 2002-08-16 2006-03-01 Schering Ag MUTANTS OF ENOS USEFUL FOR GENE THERAPY
ES2637956T3 (es) 2003-01-24 2017-10-18 Stiefel Research Australia Pty Ltd Espuma farmacéutica
AU2006259408A1 (en) 2005-06-17 2006-12-28 Genentech, Inc. Use of VEGF for wound healing
AU2007293475A1 (en) * 2006-05-31 2008-03-13 Beth Israel Deaconess Medical Center Methods of diagnosing and treating complications of pregnancy
CA2677932A1 (en) 2007-02-15 2008-08-21 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
WO2009012435A1 (en) * 2007-07-19 2009-01-22 The Trustees Of The University Of Pennsylvania Conformational entropy in molecular recognition
WO2011062155A1 (ja) * 2009-11-19 2011-05-26 タカラバイオ株式会社 変異型Ｇａｇタンパク質をコードする核酸

Also Published As

Publication number Publication date
JP7636812B2 (ja) 2025-02-27
EP4003393A1 (en) 2022-06-01
WO2021021774A1 (en) 2021-02-04
MX2022001020A (es) 2022-04-06
CA3148980A1 (en) 2021-02-04
JP2022543056A (ja) 2022-10-07
US20220265759A1 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
EP2076290B1 (en) Multimeric tie 2 agonists and uses thereof in stimulating angiogenesis
JP7145163B2 (ja) 放射線障害を予防し、組織再生を促進するための組成物および方法
JP2008526749A (ja) 自己アセンブリするペプチドナノファイバーを用いたｐｄｇｆの徐放性の送達
AU2017318610B2 (en) KIF13B-derived peptide and method of inhibiting Angiogenesis
CN116323649A (zh) 膜联蛋白a1 n-末端肽的制剂和方法
WO2015164822A1 (en) Collagen binding synthetic peptidoglycans for treatment of endothelial dysfunction
EP2310041B1 (en) Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease
JP2013536158A (ja) 創傷治癒のための新規ペプチド
US20100004165A1 (en) Novel Protein Transduction Domains and Uses Therefor
JP7636812B2 (ja) 創傷治癒を促進するための組成物および方法
CN115605218B (zh) 用于治疗大疱性表皮松解症的归巢肽引导的核心蛋白聚糖缀合物
KR20210055792A (ko) 양이온성 마크로사이클릭 펩티드의 전신 전달성, 내약성, 및 효능을 향상시키기 위한 조성물 및 방법(compositions and methods for enhancing systemic deliverability, tolerability, and efficacy of cationic macrocyclic peptides)
RU2820132C2 (ru) Способ улучшения симптомов со стороны нижних мочевыводящих путей
KR102866913B1 (ko) 화물분자 수송 도메인 sy1, 이를 포함하는 융합 화합물 및 이 융합 화합물을 포함하는 약학 조성물
CA3093763A1 (en) Method of treating benign prostatic hyperlasia with antibiotics
US6221855B1 (en) Regulation of nucleic acid expression by heparan sulfate and biological equivalents thereof
KR20220008303A (ko) 하부 요로 증상의 개선 방법
RU2772456C2 (ru) Композиции и способы для предотвращения радиационного поражения и стимуляции регенерации ткани

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000